Edison Scientific launched in November 2025 as the commercial spinout of FutureHouse, the nonprofit research group known for its modular, agentic approach to AI for science. FutureHouse was founded by neuroscientist and bioengineer Sam Rodriques and chemistry AI researcher Andrew White, whose prior work includes ChemCrow and PaperQA. The spinout was created because demand from pharmaceutical and biotech customers for expanded access and higher usage limits had outgrown what FutureHouse could support under a nonprofit structure.
The company's flagship product, Kosmos, is positioned as an 'AI scientist for R&D teams.' It autonomously reads the scientific literature, analyzes experimental and other data, generates hypotheses, and can steer investigations mid-run, executing multi-step scientific workflows with limited human oversight. Edison reports that Kosmos can compress about six months of human research effort into a single day while maintaining roughly 80 percent accuracy across diverse scientific domains, a claim aimed at the throughput bottleneck in drug discovery and chemistry research.
Edison raised a $70 million seed round at approximately a $250 million valuation, co-led by Spark Capital and Triatomic Capital along with a major US biotech investor. Angel participants reportedly include Google chief scientist Jeff Dean and CrowdStrike co-founder Dmitri Alperovitch. The company has highlighted partnerships and customer interest from organizations including Incyte and academic institutions such as MIT, reflecting early commercial traction.
Edison operates in the emerging 'AI co-scientist' category alongside efforts like Autoscience and Lila Sciences, and reflects a broader shift toward agentic systems that don't just answer questions but plan and execute research. By targeting biology and chemistry specifically, where literature volume and experimental complexity overwhelm human teams, Edison aims to become core infrastructure for pharma and biotech R&D organizations.